Prophase labs' linebacker-1 cancer therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers

Garden city, ny, may 03, 2023 (globe newswire) -- prophase labs, inc. (nasdaq: prph) (“prophase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its progress and development strategy for linebacker-1 (lb-1). linebacker is a small molecule, multi-kinase inhibitor that is being developed by the company's wholly owned subsidiary, prophase biopharma, inc. (“pbio”), as a potential mono-therapy and co-therapy option for hard-to-treat cancers. originally viewed as a co-therapy, the pre-clinical data generated has given pbio reason to believe that lb-1 will also be very effective as a mono-therapy.
PRPH Ratings Summary
PRPH Quant Ranking